Vertex Pharmaceuticals Incorporated (VRTX) Revenue by Segment & Business Profile
TRIKAFTAKAFTRIO was 74.9% of Vertex Pharmaceuticals Incorporated's revenue across the 5 lines it reports, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
- Market cap
- 132.8B
- P/E TTM
- 30.5
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 2 Nov, in 9 days
What the company does
Vertex Pharmaceuticals Incorporated is a biotechnology company in the healthcare sector. In its SEC filings it reports 5 business lines: TRIKAFTAKAFTRIO (75%), ALYFTREK (17%), Manufactured Product Other (4%), CASGEVY (2%) and others. Trailing twelve-month revenue: $12.6 billion as of 2026-06-30.
Roles we read
from the filings, not the sector label- Commercial therapies
Revenue by geography
latest quarter · company segment note| Region | Revenue | Share | y/y |
|---|---|---|---|
| United States | 2.06B | 61.7% | +11.3% |
| Europe | 978M | 29.3% | +7.3% |
| Other Countries Outsideofthe United States and Europe | 300M | 9.0% | +45.8% |
Vertex Pharmaceuticals Incorporated — questions
- What does Vertex Pharmaceuticals Incorporated do?
- Vertex Pharmaceuticals Incorporated is a biotechnology company in the healthcare sector. In its SEC filings it reports 5 business lines: TRIKAFTAKAFTRIO (75%), ALYFTREK (17%), Manufactured Product Other (4%), CASGEVY (2%) and others. Trailing twelve-month revenue: $12.6 billion as of 2026-06-30.
- How does Vertex Pharmaceuticals Incorporated make money?
- By the lines it reports in its SEC filings: TRIKAFTAKAFTRIO 74.9%, ALYFTREK 17.2%, Manufactured Product Other 4.1%, CASGEVY 2.3%, JOURNAVX 1.5% of revenue.
Every figure on this page comes from Vertex Pharmaceuticals Incorporated's own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.